Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for patients with serious bleeding and thrombotic disorders. The company leverages its deep expertise in blood clotting biology to develop a pipeline of first-in-class prophylactic therapies. Hemab's strategic focus is on addressing rare and underserved hematological conditions where current treatment options are limited or non-existent. The company's lead product candidate, HMB-001, is a bispecific antibody designed to bind and recruit Factor VIIa to activated platelets, specifically targeting Glanzmann Thrombasthenia, a severe rare bleeding disorder. Another key candidate in their pipeline is HMB-VWF, aimed at treating von Willebrand disease. By utilizing innovative engineering platforms, Hemab aims to provide long-acting, subcutaneous treatments that improve patient outcomes and quality of life. Founded by experts in the field of hematology and backed by prominent life science investors, Hemab operates with a dual presence in Denmark and the United States. The company is led by CEO Benny Sorensen, MD, PhD, who brings extensive experience in clinical development and hematology. Hemab's mission is to build a sustainable, fully integrated company that delivers life-changing medicines to patients globally, while advancing the science of hemostasis and thrombosis.
No data found.